Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammed Fatih Mulayim has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expanding the clinical spectrum of recessive CRX-associated retinal disease: an early-onset retinal dystrophy phenotype

    by M. Fatih Mulayim, Burak Acar, Yusuf Bahap, Huseyin Baran Ozdemir, Mehmet Ali Ergun

    Objective: To characterize the clinical and genetic findings in three affected siblings from a consanguineous family with a novel homozygous CRX variant and an early-onset retinal dystrophy (EORD) phenotype, and to review previously reported cases of recessive CRX -associated retinal disorders. Methods: Comprehensive ophthalmic examinations, including visual acuity testing, fundus photography, optical coherence tomography, and full-field electroretinography when available, were performed in all participants. Whole-exome sequencing (WES) was carried out on the affected individuals, followed by variant validation and familial segregation analysis. Previously reported biallelic CRX variants and their associated phenotypes were compiled from the literature for comparative analysis. Results: WES identified a novel homozygous missense variant in CRX (NM_000554.6:c.158 A > G; p.Glu53Gly) located within the homeobox domain. Segregation analysis in this consanguineous family confirmed homozygosity in all three affected siblings and heterozygosity in two unaffected siblings, consistent with autosomal recessive inheritance. Affected individuals exhibited an EORD phenotype characterized by early visual decline, macular atrophy, peripheral pigmentary changes, and severe outer retinal atrophy. Review of previously reported cases revealed that recessive CRX variants are extremely rare, with most affected individuals presenting with Leber congenital amaurosis or retinitis pigmentosa phenotypes. Conclusion: This study expands the clinical spectrum of recessive CRX -associated retinal disease by identifying an EORD phenotype caused by a homozygous CRX variant. These findings underscore the functional importance of the homeobox domain and highlight the need for further studies to clarify genotype–phenotype correlations.

  • DRD1-driven infantile dystonia: towards a mechanism-informed framework for GPCR receptoropathies

    by Gülsüm Kayhan, Ryosuke Tany, Reza Maroofian, Esra Serdaroğlu, Eon Kurumiya, Duy Phuoc Tran, Hideko Wakasugi-Masuho, Mirja Thomsen, Kamran Salayev, Rauan Kaiyrzhanov, et al.

    Despite remarkable advances in human genomics, most rare disorders remain undiagnosed, mechanistically obscure and without effective treatments. In this study, we establish DRD1, encoding the dopamine D1 receptor (D1R), as a monogenic cause of an infantile-onset dystonia syndrome, for which pharmacological responsiveness may vary depending on the underlying molecular mechanism. Across three unrelated families, eight affected individuals exhibited generalized dystonia, axial hypotonia and cognitive impairment, and carried homozygous pathogenic missense DRD1 variants. Live-cell biosensor assays revealed that patient-derived DRD1 variants disrupt receptor integrity through mechanistically diverse failures, such as trafficking deficits and impaired agonist-induced activation—ultimately converging on a collapse of D1R-mediated signalling. In line with standard clinical practice and informed by these mechanistic insights, we initiated a trial of levodopa/carbidopa in two individuals in the index family with a partial-loss-of-function variant, which was associated with improvement in voluntary motor function and cognitive engagement. Moreover, in live-cell assays, we demonstrated that Mevidalen—a selective DRD1-positive allosteric modulator currently in clinical development—substantially improved signalling in patient-derived mutants in vitro, supporting a potential future mechanism-aligned therapeutic avenue. To broaden the clinical implications of our findings, we performed a structural interpretation of DRD1 variation in 807 162 individuals and identified 29 rare predicted deleterious missense variants in heterozygous carriers. These variants clustered within evolutionarily conserved transmembrane domains and signalling motifs, providing a basis for pathogenicity assignment and variant prioritization in clinical and research settings. Building on these insights, we developed a structure-informed pharmacological experimental framework that stratifies DRD1 variants according to molecular dysfunction and matches them with mechanistically aligned therapeutic strategies—namely, orthosteric agonists, pharmacological chaperones, allosteric modulators and readthrough compounds. This in vitro approach enabled functional rescue of otherwise intractable variants, suggesting a potentially actionable molecular architecture across diverse genotypes, which remains to be tested clinically. Together, these findings identify biallelic DRD1 variants as a cause of infantile dystonia and support the potential for mechanism-informed therapeutic exploration, while emphasizing that clinical responsiveness may vary across individuals. More broadly, our integrated genomics–structure–pharmacology framework provides a proof-of-concept approach to functionally stratify G protein-coupled receptor variants, exemplified here by DRD1, and prioritize testable, mechanism-based therapeutic hypotheses for future evaluation.

  • Open Access

    Is a variant of uncertain significance always ‘insignificant’? A systematic review on PRF1 A91V in Hemophagocytic Lymphohistocytosis and comparative analysis with Still’s disease

    by İbRahim Yahya Çakır, Abdulsamet Erden, Ertuğrul Çağrı Bölek, M. Fatih Mulayim, Rahime Duran, İbRahim Karaduman, Esma Eseroğlu, Burak Karakaya, Büşra Köksoy, Ali Babazade, et al.

    Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder that may arise secondary to rheumatic diseases such as Still’s disease, where macrophage activation syndrome (MAS) represents its clinical counterpart. The pathogenic significance of the PRF1 A91V variant remains uncertain, although functional data suggest partial perforin dysfunction and a possible contribution to late-onset or atypical HLH. This study aimed to clarify the clinical implications of the PRF1 A91V variant through a systematic review of published HLH and MAS cases and a comparative analysis with a single-center Still’s disease cohort. Results: A total of 20 studies, including 38 individual HLH or MAS cases carrying the PRF1 A91V variant, were identified. The median age at diagnosis was 22 years, and 18.4% of patients were homozygous. Fever (82.6%), splenomegaly (57.9%), and hepatomegaly (36.8%) were the most frequent clinical findings. Anemia (57.1%) and thrombocytopenia (85.7%) were the predominant laboratory abnormalities, accompanied by marked hyperferritinemia (median 9319 ng/mL). Compared with 43 active Still’s disease cases, PRF1-mutated HLH patients showed significantly higher rates of cytopenias, hepatomegaly, and central nervous system involvement, together with substantially elevated ferritin levels (9,193 vs 800 ng/mL, p = 0.0023), whereas C-reactive protein levels were comparable. Receiver-operating characteristic analysis identified a ferritin cutoff of 7000 ng/mL (sensitivity 63.2%, specificity 84.6%) as the optimal discriminator for PRF1 A91V positivity. In multivariate regression, ferritin ≥ 7,000 ng/mL remained the only independent predictor (OR 17.3, 95% CI 2.0–146.3, p = 0.009). Conclusions: Patients carrying the PRF1 A91V variant represent a distinct subgroup within the spectrum of hyperinflammatory syndromes. Extreme hyperferritinemia combined with cytopenias should raise suspicion for perforin-related HLH rather than cytokine-driven MAS or classic Still’s disease. Recognition of this variant as a risk-modifying allele may guide early genetic testing and therapeutic decisions, including consideration of advanced interventions in selected cases.


  • Open Access

    Genetic Traces in Autism Spectrum Disorders: A Whole Exome Sequencing Study from Türkiye

    by Gülsüm Kayhan, Ahmet Ozaslan, Elvan Işeri, Esra Guney, Hasan Huseyin Kazan, Dicle Buyuktaskin, Muhammed Fatih Mulayim, Mehmet Ali Ergun, Ferda Emriye Percin

    Background: Autism spectrum disorders (ASDs) are defined as a large spectrum of phenotypes whose basic definition is deficiency in social interactions, particularly during pediatric stages. Through clinical evaluations, it would be challenging to diagnose since the symptoms may be disregarded or controversial. Hence, molecular approaches could be powerful for differential and certain diagnosis. Moreover, considering the possible genetic complexity of the disease, the rates of molecular diagnosis remain insufficient. Nevertheless, the number of newly identified ASD-monogenic inheritance relationships is escalating daily. This underscores the increasing importance of comprehensive molecular tests, such as whole exome sequencing (WES), which encompass all relevant genes. Furthermore, reporting population-specific variants is critical to validate already listed ones and decipher novel ones. In the present study, we aimed to document the disease-related variants in Turkish patients with ASD. Methods: This study evaluated the WES outcomes of 75 ASD patients with normal results in Fragile X testing, cytogenetic analysis, and molecular karyotyping. All patients were diagnosed with ASD based on the criteria from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). Results: The average age of the participants was 8.2 (±5.0) years. A higher percentage of the participants was male (73.3%) compared with female (26.7%). Eighteen patients (24%) had pathogenic or likely pathogenic (LP) variants, while 34 (45.3%) exhibited variants of unknown significance (VUS). In 30.7% of the cases, no clinically relevant variants were found. The MECP2 gene was most frequently affected, followed by EP300 and PTEN. Additionally, four patients carried novel de novo missense variants in the KMT2C, MECP2, PTEN, and TRRAP genes. Conclusions: Genetic diagnosis of ASD would be useful for confirming the underlying etiologies, devising personalized therapeutic strategies, and offering family counseling. Although WES has been employed in ASD patients for an extended period, the identification of gene and variant spectra across diverse cohorts and the discovery of novel variants continues to hold significant scientific importance.